Systemic Scleroderma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Scleroderma, or Systemic sclerosis (SS), is a connective tissue disorder characterized primarily by the thickening and hardening of the skin. There are two primary types of scleroderma: localized and systemic. In localized scleroderma, the disease mainly affects the skin and may impact the muscles and bones. In systemic scleroderma, there is an involvement of the internal organs, such as the digestive tract, heart, lungs, and kidneys, among others. The severity and outcome of scleroderma are variable. Genetic and environmental factors play a role in the genesis of scleroderma. Life expectancy in patients with systemic sclerosis depends on the extent and severity of internal organ involvement. Silica and certain organic solvents are recognized as risk factors for systemic scleroderma.
- The overall survival of patients with SSc ranges from 75 to 80% after five years, 55% after ten years, 35 to 40% after 15 years, and 25 to 30% after 20 years.
- SSc's age and gender-adjusted incidence rates were 15.1 per 100,000 people per year, with an adjusted prevalence of 25.9 per 100,000. SSc-ILD had an adjusted incidence rate of 1.1 per 100,000 person-years and an adjusted prevalence of 7.3 per 100,000 people.
Thelansis’s “Systemic Scleroderma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Systemic Scleroderma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Systemic Scleroderma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Systemic Scleroderma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment